<HTML>
<HEAD>
<TITLE>AOD Thesaurus Annotated Hierarchy: chemical substances by function YN YV14.4</TITLE>
<META
Name="Description"sA Guide to Concepts and Terminology in Substance Abuse and Addiction">
</META>
<META
Name="Keywords"
Content="classification thesaurus glossary dictionary definition subject heading list ontology vocabulary knowledge structure knowledge organization terminology concept">
</META>
</HEAD>
<body bgcolor="#FFFFFF">
<CENTER><B><BIG>AOD Thesaurus.&nbsp;&nbsp;Annotated Hierarchy.&nbsp;&nbsp;chemical substances by function.&nbsp;&nbsp;YN - YV14.4</BIG></B></Center>
<CENTER><A HREF="aodob.htm#Y">b-out</A>&nbsp;&nbsp;To Broad Outline&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YN">d-out</A>&nbsp;&nbsp;To Detailed Outline&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF="aodhqy.htm">qh</A>&nbsp;&nbsp;To Quick Hierarchy</CENTER>
<CENTER><A HREF="aodhnyj.htm">Previous</A>&nbsp;Annotated Hierarchy section&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm">Next</A>&nbsp;Annotated Hierarchy section&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="aodwsrch.htm">Search</A></CENTER><BR><BR>
<BR>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YN"><B><BIG>YN</BIG></B></A><SMALL>e</SMALL></TD><TD><B><TT><SMALL></TT></SMALL></B><B><BIG>therapeutic agents</BIG></B>&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YN"><SMALL>d-out</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YN"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="25%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YPe anti-AOD-abuse agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YQ anti-inflammatory, anti-infective, and antineoplastic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YR analgesics and anesthetics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YR"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YS reproductive control agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YS"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YS"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YTe agents used in body system disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+EBe metabolism &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EB"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhne.htm#EB"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+EB10e drug metabolism &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EB10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhne.htm#EB10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+EE14.4.4.2e therapeutic drug effect &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EE14-4-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhned.htm#EE14-4-4-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<BR>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP"><B>YP</B></A><SMALL>e</SMALL></TD><TD><B><TT><SMALL></TT></SMALL></B><B>anti-AOD-abuse agents</B>&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YP"><SMALL>d-out</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="25%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>This section lists pharmacologic agents used in or tested for various facets of the treatment of AOD abuse, its causes, and its consequences.  The section begins with a classification of treatment
   functions that is used throughout, keeping in mind that many of these treatment functions overlap and that many agents are used in multiple functions.  The section then is organized by substance or
   substance class being abused.  If the agent being discussed is used in treating abuse of a substance that does not fall into any of the substance classes, use the generic treatment function
   descriptor combined with the descriptor for the substance.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> pharmacologic agents for AODD </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YNe therapeutic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YN"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YN"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+GCe AODD &nbsp;&nbsp;&nbsp;<A HREF="aodhqg.htm#GC"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhng.htm#GC"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+HK2.10 AODD drug therapy &nbsp;&nbsp;&nbsp;<A HREF="aodhqhj.htm#HK2-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnhj.htm#HK2-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2">YP2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anti-AOD-abuse agents by function&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-2">YP2.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-AOD-intoxication agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.  ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.2e anti-alcohol-intoxication agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP6.2 anti-sedative-hypnotic-intoxication agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP10.2 anti-cocaine-intoxication agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.2 anti opiate intoxication agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-4">YP2.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>AOD detoxification agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.  ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>YP4.4e alcohol detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP6.4 sedative-hypnotic detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP8.4 nicotine detoxification agent &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP10.4 cocaine detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.4 opiate detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-6">YP2.6</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>AOD withdrawal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.  ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="29%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Agents for the treatment of acute AOD withdrawal and its symptoms, including substances tested for alleviation of hangover. Protracted withdrawal may cause mental/psychiatric symptoms or lead to the
   reemergence of preexisting mental disorders that must be treated; see *+YP2.8.12 agents for AOD-concurrent mental disorders* <A HREF="aodhqy.htm#YP2-8-12"><SMALL>qh</SMALL></A> <A
   HREF="aodhnyn.htm#YP2-8-12"><SMALL>ah</SMALL></A>.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.6e alcohol withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP6.6 sedative-hypnotic withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP8.6 nicotine withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP10.6 cocaine withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.6 opiate withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8">YP2.8</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>AOD relapse prevention agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.  ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> AOD dependent maintenance agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8e alcohol relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP6.8 sedative-hypnotic relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP8.8 nicotine relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP10.8 cocaine relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.8 opiate relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YW6.2.2e tianeptine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+AH20e AODD relapse &nbsp;&nbsp;&nbsp;<A HREF="aodhqa.htm#AH20"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhna.htm#AH20"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-2">YP2.8.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-AOD-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.  ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> anticraving agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8.2e anti-alcohol-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP6.8.2 anti-sedative-hypnotic-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP8.8.2 anti-nicotine-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP10.8.2 anti-cocaine-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP12.8.2 anti-opiate-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-4">YP2.8.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>AOD agonist maintenance agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>YP4.8.4 alcohol agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP8.8.4 nicotine agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP10.8.4 cocaine agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.8.4 opiate agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-6">YP2.8.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>AOD blockers&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> AOD antagonists </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8.6e alcohol blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP6.8.4 sedative-hypnotic blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP8.8.6 nicotine blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP10.8.6 cocaine blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.8.6 opiate blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-8">YP2.8.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>AOD deterrents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
<TR><TD WIDTH="31%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Substances that alter the body's response to an AOD substance, making ingestion of the substance unpleasant or toxic.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> AOD aversive agents </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> AOD sensitizing agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8.8e alcohol deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP6.8.6 sedative-hypnotic deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP8.8.8 nicotine deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-8-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP10.8.8 cocaine deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP12.8.8 opiate deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-10">YP2.8.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>conditioned AOD aversion agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
<TR><TD WIDTH="31%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Substances that have unpleasant effects and are given together with an AOD substance.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8.10e conditioned alcohol aversion agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-12">YP2.8.12</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for AOD-concurrent mental disorders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
<TR><TD WIDTH="31%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>The mental disorder may be primary (i.e., preexisting and underlying AOD abuse) or secondary (i.e., induced by AOD abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. 
   Treatment of these disorders centers mostly on relapse prevention.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> agents for mental disorder leading to AOD abuse </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> agents for mental disorder resulting from AOD abuse </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8.12e agents for alcohol-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP6.8.8 agents for sedative-hypnotic-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-8-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP8.8.10 agents for nicotine-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-8-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP10.8.10 agents for cocaine-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.8.10 agents for opiate-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YP2.6e AOD withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-12-2">YP2.8.12.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for AOD-concurrent depression&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8.12.6 agents for alcohol-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-12-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP6.8.8.2 agents for sedative-hypnotic-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-8-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP10.8.10.2 agents for cocaine-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP12.8.10.2 agents for opiate-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YW6.2.2e tianeptine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YW6e antidepressants &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-12-4">YP2.8.12.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for AOD-concurrent anxiety&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8.12.8 agents for alcohol-concurrent anxiety &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-12-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP6.8.8.4 agents for sedative-hypnotic-concurrent anxiety &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-8-8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP10.8.10.4 agents for cocaine-concurrent anxiety &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-10-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-10-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP12.8.10.4 agents for opiate-concurrent anxiety &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-10-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-10-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YW4.10e tranquilizers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP2-8-12-6">YP2.8.12.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for AOD-related cognitive impairment&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YP4.8.12.10 agents for alcohol-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-12-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP6.8.8.6 agents for sedative-hypnotic-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP6-8-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP10.8.10.6 agents for cocaine-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-10-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YP12.8.10.6 agents for opiate-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-10-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4">YP4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anti-alcohol-abuse agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> pharmacologic agents for alcoholism treatment </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-2">YP4.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-alcohol-intoxication agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> amethystic agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YH2.4.32e vasopressin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-4-32"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-4-32"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.6.8e ibuprofen &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZJ2.6.10.4.4.2.2e disulfiram &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-10-4-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-10-4-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.12e fluvoxamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZQ4.6.4e naloxone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ4-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ4-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.6.6e atipamezole &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.8.2.2.2.2e daidzin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-8-2-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-8-2-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.8.2.2.2.4e puerarin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-8-2-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-8-2-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.2e anti-AOD-intoxication agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YL2.4 ethanol antagonists &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YL2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyj.htm#YL2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-4">YP4.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alcohol detoxification agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.4e AOD detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-6">YP4.6</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alcohol withdrawal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents for the treatment of acute alcohol withdrawal and its symptoms, including substances tested for alleviation of hangover (e.g., pyritinol).  Protracted withdrawal may cause mental/psychiatric
   symptoms or lead to the reemergence of preexisting mental disorders that must be treated; see <I>agents for alcohol concurrent mental disorders</I>.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZA2.4.2.2e lithium &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZA2-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZA2-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZC12.8.10e nitrous oxide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZC12-8-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZC12-8-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF2.4.2.4 chloral hydrate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF2-4-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF2-4-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF4.2e caroverine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP8.4e bromocriptine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP32.2e apomorphine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP32-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP32-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.6.4e chlormethiazole &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.2e clonidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT4.26.2.6e dihydropyridine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.2.10e nifedipine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.12e pyrithioxin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT4.28.6.6e barbiturates &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.6.6.12e phenobarbital &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-6-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-6-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT8.4.2e carbamazepine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.6e AOD withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YP4.8.2e anti-alcohol-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YT8.14e calcium channel blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-14"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT8-14"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YV14.2.2e alpha-adrenergic receptor agonists &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV14-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV14-2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-6-2">YP4.6.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>lofexidine&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-6-4">YP4.6.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>slumazenil&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-6-6">YP4.6.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>beta blockers for alcohol withdrawal&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZN2.16.2.12.4.2e propranolol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-12-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-12-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.18e atenolol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-18"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-18"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-6-8">YP4.6.8</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>benzodiazepines for alcohol withdrawal&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZT6.4.2.2e alprazolam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.8e clonazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT6.4.2.8.12e diazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.18e flurazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-18"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-18"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.20e lorazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-20"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-20"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.24e oxazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-24"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-24"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.28e prazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-28"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-28"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.30e temazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-30"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-30"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.32e halazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-32"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-32"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT6.4.2.10e chlordiazepoxide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.10.2e clorazepate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+ZT6.4.2e benzodiazepines &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-6-10">YP4.6.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-alcohol-related-delirium agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZG4.4.2e haloperidol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZG4-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZG4-4-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-6-12">YP4.6.12</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-alcohol-related-seizures agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6-12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZG8.4.4e valproic acid &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZG8-4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZG8-4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.6.2e phenytoin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.6.6.12e phenobarbital &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-6-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-6-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT8.4.2e carbamazepine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-4-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8">YP4.8</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alcohol relapse prevention agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> alcohol dependent maintenance agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8e AOD relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2">YP4.8.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-alcohol-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> alcohol intake reduction agents </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> anti-dipsotropic agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>YH2.2.2e melatonin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.8.2.2.2.2e daidzin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-8-2-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-8-2-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.8.2.2.2.4e puerarin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-8-2-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-8-2-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.2e anti-AOD-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YP4.6e alcohol withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2-2">YP4.8.2.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>serotonergic anti-alcohol-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YV6.6.2e serotonin uptake inhibitors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV6-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YV6.6.2.2 viqualine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV6-6-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF8.6.2.2.2e sertraline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF8-6-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF8-6-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.4.2e fluoxetine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.4.4e citalopram &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.12e fluvoxamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT4.26.4.2.2e zimelidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.4.2.2.2e norzimelidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-4-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-4-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.2e buspirone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2-2-2">YP4.8.2.2.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alaproclate&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="35%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2-2-4">YP4.8.2.2.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>femoxetine&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-2-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="35%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2-2-6">YP4.8.2.2.6</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>indalpine&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-2-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="35%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2-4">YP4.8.2.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>dopaminergic anti-alcohol-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZP8.4e bromocriptine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2-6">YP4.8.2.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>GABA receptor agonist anti-alcohol-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZJ2.10.4.2e gamma-hydroxybutyric acid &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.10.8.2.2.2.2e calcium acetylhomotaurinate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-8-2-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-8-2-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.10.8.2.2.2.4e bis acetyl homotaurine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-8-2-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-8-2-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2-8">YP4.8.2.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>narcotic antagonist anti-alcohol-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZQ4.6.4e naloxone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ4-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ4-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZQ4.6.6e naltrexone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ4-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ4-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZQ4.8.6e nalmefene &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ4-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ4-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.10 ondansetron &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-2-10">YP4.8.2.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>neuropeptide anti-alcohol-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YH2.4.2e thyrotropin RH &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YH2.4.14e adrenocorticotropic hormone &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-4-14"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-4-14"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YH2.4.32e vasopressin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-4-32"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-4-32"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YH2.4.36e cholecystokinin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-4-36"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-4-36"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YV6.6.2.4 amterozide &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV6-6-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.6.4e ritanserin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+ZO4.24e neuropeptides &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO4-24"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO4-24"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-4">YP4.8.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alcohol agonist maintenance agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.4 AOD agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-6">YP4.8.6</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alcohol blockers&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> alcohol antagonists </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZQ4.6.6e naltrexone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ4-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ4-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.6 AOD blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-8">YP4.8.8</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alcohol deterrents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="31%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Substances that alter the body's response to alcohol, making its ingestion unpleasant or toxic.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> alcohol aversive agents </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> alcohol sensitizing agents </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> antidipsotropic agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZC12.6.2.2e citrated calcium carbimide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZC12-6-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZC12-6-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZJ2.6.10.4.4.2.2e disulfiram &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-10-4-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-10-4-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.6.8e nitrefazole &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-6-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-6-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.8 AOD deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-10">YP4.8.10</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>conditioned alcohol aversion agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="31%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Substances that have unpleasant effects and are given together with alcohol.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+ZN2.16.2.10.2e succinylcholine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP32.2e apomorphine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP32-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP32-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.12.2e emetine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.10 conditioned AOD aversion agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-12">YP4.8.12</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for alcohol-concurrent mental disorders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="31%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>The mental disorder may be primary (i.e., preexisting and underlying alcohol abuse) or secondary (i.e., induced by alcohol abuse), or symptoms may be caused by or occur with acute and protracted
   withdrawal.  Treatment of these disorders centers mostly on relapse prevention.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12 agents for AOD-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-12-2">YP4.8.12.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>dopaminergic blockers for alcohol-concurrent mental disorders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZN2.20.6.4e tiapride &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-20-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-20-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.14.12e thioridazine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-14-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-14-12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-12-4">YP4.8.12.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>dopaminergic agonists for alcohol-concurrent mental disorders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZP8.4e bromocriptine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP32.2e apomorphine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP32-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP32-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-12-6">YP4.8.12.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for alcohol-concurrent depression&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD>+YV6.6.2e serotonin uptake inhibitors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV6-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW6.4e MAO inhibitors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZA2.4.2.2e lithium &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZA2-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZA2-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF8.10.2.2e amitriptyline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF8-10-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF8-10-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.4.2e fluoxetine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.4e imipramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.6e desipramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.8.2e doxepin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12.2 agents for AOD-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW6e antidepressants &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-12-8">YP4.8.12.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for alcohol-concurrent anxiety&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YW6.4.2 phenelzine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.12.4.2e propranolol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-12-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-12-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.2e clonidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.2e buspirone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT6.4.2e benzodiazepines &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.2e alprazolam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.4e imipramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12.4 agents for AOD-concurrent anxiety &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW4.10e tranquilizers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-12-10">YP4.8.12.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for alcohol-related cognitive impairment&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD>+YV6.6.2e serotonin uptake inhibitors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV6-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.12e fluvoxamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.2e clonidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12.6 agents for AOD-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP4-8-12-10-2">YP4.8.12.10.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>piridoxilate&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-10-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6">YP6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anti-sedative-hypnotic-abuse agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents mentioned here may also apply to alcohol dependence.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-2">YP6.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-sedative-hypnotic-intoxication agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.2e anti-AOD-intoxication agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-4">YP6.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>sedative-hypnotic detoxification agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.4e AOD detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-6">YP6.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>sedative-hypnotic withdrawal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents for the treatment of acute sedative-hypnotic withdrawal.  Protracted withdrawal may cause mental/psychiatric symptoms that must be treated, see *+YP6.8.8 agents for
   sedative-hypnotic-concurrent mental disorders* <A HREF="aodhqy.htm#YP6-8-8"><SMALL>qh</SMALL></A> <A HREF="aodhnyn.htm#YP6-8-8"><SMALL>ah</SMALL></A>.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.6e AOD withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-6-2">YP6.6.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>barbiturate withdrawal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZT4.28.6.6.10e pentobarbital &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-6-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-6-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.6.6.12e phenobarbital &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-6-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-6-12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-6-4">YP6.6.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>benzodiazepine withdrawal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-6-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD>+ZT6.4.2.8.12e diazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-8">YP6.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>sedative-hypnotic relapse prevention agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> sedative-hypnotic dependent maintenance agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8e AOD relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-8-2">YP6.8.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-sedative-hypnotic-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> sedative-hypnotic intake reduction agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.2e anti-AOD-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-8-4">YP6.8.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>sedative-hypnotic blockers&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents that block the mood-altering or analgesic effects of sedative-hypnotics.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.6 AOD blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-8-6">YP6.8.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>sedative-hypnotic deterrents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.8 AOD deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-8-8">YP6.8.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for sedative-hypnotic-concurrent mental disorders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>The mental disorder may be primary (i.e., preexisting and underlying sedative-hypnotic abuse) or secondary (i.e., induced by sedative-hypnotic abuse), or symptoms may be caused by or occur with acute
   and protracted withdrawal.  Treatment of these disorders centers mostly on relapse prevention.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12 agents for AOD-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-8-8-2">YP6.8.8.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for sedative-hypnotic-concurrent depression&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.12.2 agents for AOD-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW6e antidepressants &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-8-8-4">YP6.8.8.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for sedative-hypnotic-concurrent anxiety&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.12.4 agents for AOD-concurrent anxiety &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW4.10e tranquilizers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP6-8-8-6">YP6.8.8.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for sedative-hypnotic-related cognitive impairment&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP6-8-8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.12.6 agents for AOD-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8">YP8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anti-nicotine-abuse agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZT4.14.2e clonidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-2">YP8.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>busprione&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-4">YP8.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nicotine detoxification agent&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> nicotine substitution agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.4e AOD detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-4-2">YP8.4.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nicotin gum&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-6">YP8.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nicotine withdrawal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents for the treatment of acute nicotine withdrawal.  Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see <I>agents for nicotine concurrent mental disorders</I>.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.6e AOD withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>YP8.8.2 anti-nicotine-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-8">YP8.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nicotine relapse prevention agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> nicotine dependent maintenance agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8e AOD relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-8-2">YP8.8.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-nicotine-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> nicotine intake reduction agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.2e anti-AOD-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>YP8.6 nicotine withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP8-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-8-4">YP8.8.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nicotine agonist maintenance agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.4 AOD agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-8-6">YP8.8.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nicotine blockers&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents that block the mood-altering or analgesic effects of nicotine.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> nicotine antagonist maintenance agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZU6.2e mecamylamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZU6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZU6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.6 AOD blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-8-8">YP8.8.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nicotine deterrents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> nicotine aversive agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.8 AOD deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP8-8-10">YP8.8.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for nicotine-concurrent mental disorders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP8-8-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>The mental disorder may be primary (i.e., preexisting and underlying nicotine abuse) or secondary (i.e., induced by nicotine abuse), or symptoms may be caused by or occur with acute and protracted
   withdrawal.  Treatment of these disorders centers mostly on relapse prevention.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12 agents for AOD-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10">YP10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anti-cocaine-abuse agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-2">YP10.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-cocaine-intoxication agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.2e anti-AOD-intoxication agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-4">YP10.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>cocaine detoxification agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.4e AOD detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-6">YP10.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>cocaine withdrawal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents for the treatment of acute cocaine withdrawal.  Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see <I>agents for cocaine concurrent mental disorders</I>.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.6e AOD withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YP10.8.2 anti-cocaine-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8">YP10.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>cocaine relapse prevention agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> cocaine dependent maintenance agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZQ6.2e buprenorphine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT8.4.2e carbamazepine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.16.2.2e flupenthixol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-16-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-16-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8e AOD relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-2">YP10.8.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-cocaine-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZF8.2 amantadine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZO2e amino acids &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZO2.2.2.14e tryptophan &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO2-2-2-14"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO2-2-2-14"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZO2.2.4.10e tyrosine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO2-2-4-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO2-2-4-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.6e carbamazepin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.6e desipramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.16.2.2e flupenthixol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-16-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-16-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.2e anti-AOD-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>YP10.6 cocaine withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-2-2">YP10.8.2.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>bupropion&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-4">YP10.8.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>cocaine agonist maintenance agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.4 AOD agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-6">YP10.8.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>cocaine blockers&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents that block the mood-altering or analgesic effects of cocaine.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> cocaine antagonist maintenance agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZG4.4.2e haloperidol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZG4-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZG4-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP8.4e bromocriptine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.18.4e trazodone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-18-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-18-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.4e imipramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.6 AOD blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YV6 neuroregulator blockaders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-8">YP10.8.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>cocaine deterrents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> cocaine aversive agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.8 AOD deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-10">YP10.8.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for cocaine-concurrent mental disorders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>The mental disorder may be primary (i.e., preexisting and underlying cocaine abuse) or secondary (i.e., induced by cocaine abuse), or symptoms may be caused by or occur with acute and protracted
   withdrawal.  Treatment of these disorders centers mostly on relapse prevention.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZJ2.4e methylphenydate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.16.4.2e magnesium pemoline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-16-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-16-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12 agents for AOD-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-10-2">YP10.8.10.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for cocaine-concurrent depression&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-10-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZF8.4 maprotiline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.18.4e trazodone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-18-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-18-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.4e imipramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.6e desipramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.8.2e doxepin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12.2 agents for AOD-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW6e antidepressants &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-10-4">YP10.8.10.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for cocaine-concurrent anxiety&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-10-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZT8.2.2.6e desipramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12.4 agents for AOD-concurrent anxiety &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW4.10e tranquilizers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP10-8-10-6">YP10.8.10.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for cocaine-related cognitive impairment&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-10-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>*GZ12.2.2 attention deficit disorder with hyperactivity* <A HREF="aodhqg.htm#GZ12-2-2"><SMALL>qh</SMALL></A> <A HREF="aodhngz.htm#GZ12-2-2"><SMALL>ah</SMALL></A> in particular is associated with
   cocaine abuse.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZJ2.10.4.8e methylphenidate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-4-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-4-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.16.4.2e magnesium pemoline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-16-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-16-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12.6 agents for AOD-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12">YP12</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anti-opiate-abuse agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-2">YP12.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti opiate intoxication agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZQ4.6.4e naloxone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ4-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ4-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.2e anti-AOD-intoxication agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-4">YP12.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>opiate detoxification agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZQ4.6.6e naltrexone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ4-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ4-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZQ10.2e methadone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.2e clonidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.4e AOD detoxification agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-6">YP12.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>opiate withdrawal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents for the treatment of acute opiate withdrawal.  Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see <I>agents for opiate concurrent mental disorders</I>.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+ZQ10.2e methadone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.2e clonidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.6e AOD withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>YP12.8.2 anti-opiate-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8">YP12.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>opiate relapse prevention agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> opiate dependent maintenance agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8e AOD relapse prevention agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8-2">YP12.8.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anti-opiate-craving agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> opiate intake reduction agents </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.2e anti-AOD-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YP12.6 opiate withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.8.4 opiate agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP12.8.6 opiate blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8-4">YP12.8.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>opiate agonist maintenance agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZQ6.2e buprenorphine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZQ10.2e methadone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZQ10.4e LAAM &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ10-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ10-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.4 AOD agonist maintenance agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>YP12.8.2 anti-opiate-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8-6">YP12.8.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>opiate blockers&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents that block the mood-altering or analgesic effects of opiates.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> opiate antagonist maintenance agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZQ4.6.6e naltrexone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ4-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ4-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.6 AOD blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>YP12.8.2 anti-opiate-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP12-8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8-8">YP12.8.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>opiate deterrents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.8 AOD deterrents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8-10">YP12.8.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for opiate-concurrent mental disorders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>The mental disorder may be primary (i.e., preexisting and underlying opiate abuse) or secondary (i.e., induced by opiate abuse), or symptoms may be caused by or occur with acute and protracted
   withdrawal.  Treatment of these disorders centers mostly on relapse prevention.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP2.8.12 agents for AOD-concurrent mental disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8-10-2">YP12.8.10.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for opiate-concurrent depression&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-10-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.12.2 agents for AOD-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW6e antidepressants &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8-10-4">YP12.8.10.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for opiate-concurrent anxiety&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-10-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.12.4 agents for AOD-concurrent anxiety &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW4.10e tranquilizers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YP12-8-10-6">YP12.8.10.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>agents for opiate-related cognitive impairment&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP12-8-10-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP2.8.12.6 agents for AOD-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP2-8-12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP2-8-12-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<BR>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ"><B>YQ</B></A><SMALL></SMALL></TD><TD><B><TT><SMALL></TT></SMALL></B><B>anti-inflammatory, anti-infective, and antineoplastic agents</B>&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YQ"><SMALL>d-out</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="25%"> </TD><TD WIDTH="5%">BT</TD><TD>+YNe therapeutic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YN"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YN"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ2">YQ2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anti-inflammatory agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD><TD WIDTH="5%">ST</TD><TD> tissue protective agents </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> tissue repair agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZN2.18.2.2.2.2.2e R alpha methylhistamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-18-2-2-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-18-2-2-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ2-2">YQ2.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nonsteroidal anti-inflammatory drugs&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> NSAID </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YR2.2.6 gout suppressants &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YR2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZJ2.10.10.2.4.2.4e salicylate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-10-2-4-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-10-2-4-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.24.4e antipyrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-24-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-24-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.30.12e tolmetin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-30-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-30-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.34.2e piroxicam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-34-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-34-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.10.6e indomethacin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-10-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ2-4">YQ2.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>steroidal anti-inflammatory drugs&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ2-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YH4.6.2.2e dexamethasone &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH4-6-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH4-6-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZV8.2.2.2e prednisone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV8-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV8-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZV8.2.4.2e prednisolone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV8-2-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV8-2-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+ZVe steroids &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4">YQ4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anti-infective agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD><TD WIDTH="5%">NT</TD><TD>+YT12.2 urinary anti-infective agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZN2.20.8e sulfonamide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-20-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-20-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-2">YQ4.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>local anti-infective agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZJ2.6.10.4.4.4.2e thiram &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-10-4-4-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-10-4-4-4-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-4">YQ4.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antitubercular agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZF6.6e isoniazid &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+GH16.14.4.2e tuberculosis &nbsp;&nbsp;&nbsp;<A HREF="aodhqg.htm#GH16-14-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhngf.htm#GH16-14-4-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-6">YQ4.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antibacterial agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZT6.24.2e ciprofloxacin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-24-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-24-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-6-2">YQ4.6.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>leprostatic agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YQ4.14.16.2 rifampin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-16-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ4-14-16-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.10.10.6.2.2e thalidomide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-10-6-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-10-6-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>GH16.14.4.4 Hansen's disease &nbsp;&nbsp;&nbsp;<A HREF="aodhqg.htm#GH16-14-4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhngf.htm#GH16-14-4-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-8">YQ4.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antifungal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD>+YQ4.14.6 antifungal antibiotics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ4-14-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.6.10.4.4.4.2e thiram &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-10-4-4-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-10-4-4-4-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-10">YQ4.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antiparasitic agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZT4.32.4e kainate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-32-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-32-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-10-2">YQ4.10.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anthelmintics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-10-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-10-4">YQ4.10.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antiprotozoal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-10-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-10-4-2">YQ4.10.4.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antimalarials&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-10-4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZP4.4e quinine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.4e pyrimethamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.2e quinacrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-12">YQ4.12</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antiviral agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YE10.8.4e interferon &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YE10-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YE10-8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-12-2">YQ4.12.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>acyclovir&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-12-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14">YQ4.14</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antibiotics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YD8.12.2e ionophores &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YD8-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YD8-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF2.4.2.8.2e chloramphenicol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF2-4-2-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF2-4-2-8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-2">YQ4.14.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>aminoglycoside antibiotics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD>+ZG8.2.2.2e gentamicin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZG8-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZG8-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZG8.2.2.4e neomycin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZG8-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZG8-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-4">YQ4.14.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antitubercular antibiotics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YQ4.14.16.2 rifampin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-16-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ4-14-16-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-6">YQ4.14.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antifungal antibiotics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZT4.20.8.2e cycloheximide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-20-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-20-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YQ4.8 antifungal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ4-8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-6-2">YQ4.14.6.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>griseofulvin&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">BT</TD><TD>+YD8.2 ADH antagonists &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YD8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YD8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-6-4">YQ4.14.6.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nystatin&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-6-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-8">YQ4.14.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antineoplastic antibiotics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">BT</TD><TD>+YQ6 antineoplastic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-10">YQ4.14.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>lactam antibiotics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-10-2">YQ4.14.10.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>moxalactam&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-10-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-10-4">YQ4.14.10.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>penicillin&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-10-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-10-4-2">YQ4.14.10.4.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>penicillin G&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-10-4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="35%"> </TD><TD WIDTH="5%">ST</TD><TD> penicillin G benzathine </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> penicillin G procaine </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-12">YQ4.14.12</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>macrolide antibiotics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-12-2">YQ4.14.12.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>amphotericin&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-12-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-12-4">YQ4.14.12.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>erythromycin&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-12-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-14">YQ4.14.14</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>bacitracin&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-14"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-16">YQ4.14.16</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>rifamycins&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-16"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-16-2">YQ4.14.16.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>rifampin&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-16-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">BT</TD><TD>+YQ4.6.2 leprostatic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ4-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YQ4.14.4 antitubercular antibiotics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ4-14-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-18">YQ4.14.18</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>tetracyclines&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-18"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ4-14-20">YQ4.14.20</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>combined antibiotics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-20"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YQ6">YQ6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>antineoplastic agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD><TD WIDTH="5%">ST</TD><TD> anti-neoplastic agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>YQ4.14.8 antineoplastic antibiotics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4-14-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ4-14-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.6.10.4.6e urethane &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-10-4-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-10-4-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.20.6.8e procarbazine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-20-6-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-20-6-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.2.2.2e quinacrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZV8.2.2.2e prednisone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV8-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV8-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>YE12e immunosuppressive agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YE12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YE12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<BR>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR"><B>YR</B></A><SMALL></SMALL></TD><TD><B><TT><SMALL></TT></SMALL></B><B>analgesics and anesthetics</B>&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YR"><SMALL>d-out</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="25%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YNe therapeutic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YN"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YN"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR2">YR2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>analgesics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Substances that reduce pain and that may or may not have other psychoactive properties.  See *+ZQ opioids* <A HREF="aodhqz.htm#ZQ"><SMALL>qh</SMALL></A> <A
   HREF="aodhnzp.htm#ZQ"><SMALL>ah</SMALL></A>.  
  <BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drugs that relieve pain without blocking the conduction of nerve impulses or markedly altering the function of the sensory apparatus.  The narcotic analgesics
   act on the central nervous system, produce dependence, and alter the patient's perception; they are primarily used for severe pain.  The nonnarcotic analgesics act at the site of pain, do not
   produce dependence, and do not alter the patient's perception; they are used for mild to moderate pain.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YW4.2e narcotic analgesics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.10.10.4.2e tilidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-10-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-10-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>GC2.6 abuse of non-dependence-producing substance &nbsp;&nbsp;&nbsp;<A HREF="aodhqg.htm#GC2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhng.htm#GC2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+HU2e analgesia &nbsp;&nbsp;&nbsp;<A HREF="aodhqhj.htm#HU2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnhj.htm#HU2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR2-2">YR2.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>nonnarcotic analgesics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>The nonnarcotic analgesics act at the site of pain, do not produce dependence, and do not alter the patient's perception; they are used for mild to moderate pain.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> anti-inflammatory analgesics </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> non-opioid analgesics </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+ZJ2.10.10.2.4.2.4e salicylate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-10-2-4-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-10-2-4-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.24.4e antipyrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-24-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-24-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.30.12e tolmetin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-30-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-30-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.34.2e piroxicam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-34-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-34-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR2-2-2">YR2.2.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>prescription nonnarcotic analgesics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR2-2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR2-2-4">YR2.2.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>non-prescription nonnarcotic analgesics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR2-2-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR2-2-6">YR2.2.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>gout suppressants&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR2-2-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZN2.20.2.2.6e phenacetin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-20-2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-20-2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP6e colchicine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.10.6e indomethacin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-10-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YQ2.2 nonsteroidal anti-inflammatory drugs &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR2-2-6-2">YR2.2.6.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>uricosuric agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR2-2-6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR4">YR4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>anesthetics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="27%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Agents that produce a local or general loss of sensation, including pain.  Local anesthesia involves loss of sensation in one area of the body by blockage of conduction in nerves.  General anesthesia
   involves loss of consciousness, usually for the purpose of relieving pain during surgery.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YW4.4e general anesthetics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZC12.8.10e nitrous oxide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZC12-8-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZC12-8-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF4.4e propofol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.6.10.2.4.2e sodium oxybate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-10-2-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-10-2-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZL2.6.4e chloroform &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZL2-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZL2-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZL2.6.8e trichloroethylene &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZL2-6-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZL2-6-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT4.28.6.6e barbiturates &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+HU4e anesthesia &nbsp;&nbsp;&nbsp;<A HREF="aodhqhj.htm#HU4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnhj.htm#HU4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YW4.4e general anesthetics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YR4-2">YR4.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>local anesthetics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YR4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="29%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Agents that block conduction in nerve axons in the peripheral nervous system when applied locally to nerve tissue.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> anesthetic, local </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+BK2e cocaine &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BK2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnbg.htm#BK2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.10.10.2.2.2.4e procaine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-10-2-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-10-2-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<BR>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YS"><B>YS</B></A><SMALL></SMALL></TD><TD><B><TT><SMALL></TT></SMALL></B><B>reproductive control agents</B>&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YS"><SMALL>d-out</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YS"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="25%"> </TD><TD WIDTH="5%">ST</TD><TD> contraceptive agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZK4.4.8.6.2e misoprostol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZK4-4-8-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZK4-4-8-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YNe therapeutic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YN"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YN"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>HS4.2e contraception &nbsp;&nbsp;&nbsp;<A HREF="aodhqhj.htm#HS4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnhj.htm#HS4-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YS2">YS2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>female contraceptive agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YS2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD><TD WIDTH="5%">ST</TD><TD> birth control pills </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZV6.2e mifepristone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YH4.10.4 synthetic progestational hormones &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH4-10-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH4-10-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZV22e synthetic steroids &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV22"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV22"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YS4">YS4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>male contraceptive agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YS4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<BR>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT"><B>YT</B></A><SMALL>e</SMALL></TD><TD><B><TT><SMALL></TT></SMALL></B><B>agents used in body system disorders</B>&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YT"><SMALL>d-out</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="25%"> </TD><TD WIDTH="5%">NT</TD><TD>+YV peripheral nervous system agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YNe therapeutic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YN"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YN"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT2">YT2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>appetite suppressants&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Agents used to reduce hunger and diminish food intake in the treatment of obesity.  
  <BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Also called anorexiants or anorectic agents.  Most of these drugs are sympathomimetic amines, whose efficacy is limited by associated insomnia, dependence
   phenomena, and other adverse effects.  Amphetamines formerly were used for their appetite-suppressing effects.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> anorectic agents </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> anorexiants </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> appetite depressants </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+BJ2.2e amphetamines &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BJ2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnbg.htm#BJ2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZN2.10.2e fenfluramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-10-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT4">YT4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>antimetabolites&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZT4.26.10.4e pyrithiamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-10-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-10-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT4.28.6.8.2e thiouracil &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.6.8.2.2e propylthiouracil &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-8-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-8-2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT6">YT6</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>neuromuscular agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT6-2">YT6.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>central muscle relaxants&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZJ2.6.10.4.2e meprobamate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-10-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-10-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.28e prazepam &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-28"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-28"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT6-4">YT6.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>neuromuscular blocking agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT6-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT6-4-2">YT6.4.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>curare&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT6-4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">RT</TD><TD>+ZPe alkaloids &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT6-6">YT6.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>neuromuscular depolarizing agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT6-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD>+ZN2.16.2.10.2e succinylcholine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-10-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT8">YT8</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>cardiovascular agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT8-2">YT8.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antiarrhythmia agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZJ2.10.10.2.2.2.2e procainamide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-10-2-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-10-2-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.12.4.2e propranolol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-12-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-12-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP4.2e quinidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP20e sparteine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP20"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP20"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.6.2e phenytoin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YT8.6e vasodilator agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT8-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT8-4">YT8.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>vasoconstrictor agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> vasopressor agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YH2.4.6e angiotensin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-4-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-4-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YH2.4.32e vasopressin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-4-32"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-4-32"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YT8.12e calcium channel agonists &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT8-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.4e phenylephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.20e methoxamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-20"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-20"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>EL4.10e vasoconstriction &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EL4-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhneh.htm#EL4-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT8-6">YT8.6</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>vasodilator agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 1995.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>BC4 theophylline &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BC4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnb.htm#BC4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YT8.14e calcium channel blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-14"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT8-14"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZC12.6.4.2e sodium nitroprusside &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZC12-6-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZC12-6-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZC12.8.6.2e amyl nitrite &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZC12-8-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZC12-8-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZC12.8.6.4e butyl nitrite &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZC12-8-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZC12-8-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF2.2.4.2e ifenprodil &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF2-2-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF2-2-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF2.12.2.2e nitroglycerin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF2-12-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF2-12-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF2.12.8.2.2e isosorbide dinitrate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF2-12-8-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF2-12-8-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZF4.6e resveratrol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF4-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF4-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.12.4.2e propranolol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-12-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-12-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.16e suloctidil &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-16"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-16"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YT8.2 antiarrhythmia agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT8-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT8-8">YT8.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antihypertensive agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> hypertensive medication </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZC12.6.4.2e sodium nitroprusside &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZC12-6-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZC12-6-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.10.6e phenoxybenzamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-10-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.12.4.2e propranolol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-12-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-12-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZO2.2.8.6.2e captopril &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO2-2-8-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO2-2-8-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP18.4.4e nimodipine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP18-4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP18-4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZP26e rauwolfia alkaloids &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP26"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP26"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.2e clonidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.12e phentolamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.2.6.4e isradipine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.2.6.6e nitrendipine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.20.6e prazosin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-20-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-20-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT8-10">YT8.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>cardiotonic agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD>+YH2.2.6.6e norepinephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-2-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-2-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZG8.2.6e cardiac glycosides &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZG8-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZG8-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.4e phenylephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT8-12">YT8.12</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>calcium channel agonists&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.  ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZT4.26.2.6.2e Bay K 8644 &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YT8.4e vasoconstrictor agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT8-14">YT8.14</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>calcium channel blockers&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-14"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZF4.2e caroverine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZM4e verapamil &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZM4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZM4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP18.4.4e nimodipine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP18-4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP18-4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.20.6e perhexiline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-20-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-20-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.2.6.4e isradipine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.2.6.6e nitrendipine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.2.10e nifedipine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YT8.6e vasodilator agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YP4.6e alcohol withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10">YT10</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>gastrointestinal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YC4.10.4.2e pepsin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YC4-10-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YC4-10-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YG6 gastrointestinal hormones &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YG6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YG6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10-2">YT10.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>emetic agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Changed descriptor 2000; through 1999 use "emetics."  ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="29%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Agent that causes vomiting.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> emetics </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YV6 neuroregulator blockaders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YV6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10-2-2">YT10.2.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>ipecac&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">BT</TD><TD>+ZPe alkaloids &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+HK2.12.2e chemical aversion therapy &nbsp;&nbsp;&nbsp;<A HREF="aodhqhj.htm#HK2-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnhj.htm#HK2-12-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10-4">YT10.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>laxatives&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">RT</TD><TD><TT>&nbsp;</TT>BN other specific drug of abuse &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BN"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnbg.htm#BN"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10-6">YT10.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antidiarrheals&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZH10e pectin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZH10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZH10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10-8">YT10.8</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antiulcer agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZH8.4.2.2e sucralfate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZH8-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZH8-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZK4.4.8.6.2e misoprostol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZK4-4-8-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZK4-4-8-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.12.4e ranitidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-12-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.36.2e famotidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-36-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-36-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.38e cimetidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-38"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-38"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.34e omeprazole &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-34"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-34"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10-10">YT10.10</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>bile acids and salts&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>EB26e bile acid metabolism &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EB26"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhne.htm#EB26"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZV10.2e cholic acid &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZV10.2.2.2e chenodeoxycholic acid &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV10-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV10-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>XM6.6e bile &nbsp;&nbsp;&nbsp;<A HREF="aodhqx.htm#XM6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnxf.htm#XM6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZV10e cholanes &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZV10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZV10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10-12">YT10.12</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>cathartics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT10-14">YT10.14</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antisecretory agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-14"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> antisecretory drugs </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZT4.12.4e ranitidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-12-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.38e cimetidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-38"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-38"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.4.2.8.34e omeprazole &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-4-2-8-34"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-4-2-8-34"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT12">YT12</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>urinary system agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT12-2">YT12.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>urinary anti-infective agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT12-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD>+ZT4.12.2e nitrofuran &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YQ4e anti-infective agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YQ4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YQ4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT12-4">YT12.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>renal agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT12-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT12-4-2">YT12.4.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>diuretics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT12-4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 1995.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>YG34.2.2 spironolactone &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YG34-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YG34-2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14">YT14</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>hematologic agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14-2">YT14.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>anticoagulants&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> anticoagulant drugs </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZO6.8.12.12e protein C &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO6-8-12-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO6-8-12-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>EE16.6e antagonistic drug interaction &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EE16-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhned.htm#EE16-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14-4">YT14.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>coagulants&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">RT</TD><TD>+ZO6.4.10.6.4e blood coagulation factors &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO6-4-10-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO6-4-10-6-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14-6">YT14.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>platelet aggregation inhibitors&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZJ2.10.10.2.4.2.2e acetylsalicylic acid &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-10-2-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-10-2-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZK4.4.8.2e prostacyclin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZK4-4-8-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZK4-4-8-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.20.2e ketanserin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-20-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-20-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14-6-2">YT14.6.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>hemostatics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14-6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YC4.10.4.8.4e thrombin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YC4-10-4-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YC4-10-4-8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14-6-4">YT14.6.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>heparin antagonists&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14-6-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>YB18e vitamin K &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YB18"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YB18"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>EE16.6e antagonistic drug interaction &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EE16-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhned.htm#EE16-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14-8">YT14.8</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>fibrinolytic agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14-8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> antithrombotic agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>YC4.10.4.4e plasminogen activator &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YC4-10-4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YC4-10-4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YC4.10.4.8.12 streptokinase &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YC4-10-4-8-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YC4-10-4-8-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YC18.2e plasminogen &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YC18-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YC18-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14-10">YT14.10</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>hematinics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14-10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD>+YB12.24e vitamin B12 &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YB12-24"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YB12-24"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YT14-12">YT14.12</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>plasma substitutes&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT14-12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZH10e pectin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZH10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZH10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV">YV</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;</TT></SMALL></B>peripheral nervous system agents&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YV"><SMALL>d-out</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="27%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
<TR><TD WIDTH="27%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>Many of these agents also have secondary effects on the central nervous system.
  </TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YTe agents used in body system disorders &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV2">YV2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>bronchodilator agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> bronchodilators </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>BC4 theophylline &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BC4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnb.htm#BC4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YH2.2.6e epinephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.4e phenylephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV4">YV4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>neuroregulators&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">NT</TD><TD>+YH2.2.6e epinephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YH2.2.6.6e norepinephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-2-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-2-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>YH2.4.36e cholecystokinin &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-4-36"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-4-36"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZJ2.6.10.2.2e aminobutyric acid &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-6-10-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-6-10-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZN2.18.2e acetylcholine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-18-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-18-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZO4.24e neuropeptides &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO4-24"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO4-24"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZO4.24.4.4.2e substance P &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO4-24-4-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO4-24-4-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZQ20.2e endorphins &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ20-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ20-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.10.12.4e serotonin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-10-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-10-12-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YJ2e neurotransmitters &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YJ2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyj.htm#YJ2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV4-2">YV4.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>dopaminergic agents&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD>+ZN2.8.4e dopa &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZN2.8.6e dopamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-8-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP32.2e apomorphine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP32-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP32-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.12.6e nomifensine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-12-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6">YV6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>neuroregulator blockaders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD><TD WIDTH="5%">ST</TD><TD> neuroregulator blockers </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YT10.2e emetic agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YT10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YT10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YP10.8.6 cocaine blockers &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP10-8-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP10-8-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6-2">YV6.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>antiemetics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> anti-emetic agents </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZT8.14.10e promethazine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-14-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-14-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6-4">YV6.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>histamine antagonists&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">RT</TD><TD><TT>&nbsp;</TT>EE16.6e antagonistic drug interaction &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EE16-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhned.htm#EE16-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6-4-2">YV6.4.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>histamine H1 receptor blockaders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-4-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>A group of therapeutic drugs used in the treatment of allergic disorders (and sometimes, because of their mild sedating effects, to allay anxiety and induce sleep).  Usually they are abused with
   codeine or alcohol because they act synergistically to magnify the sedative effects of both.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> antihistamines </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> antihistaminics </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> H1 blockers </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZT4.26.2.2e pyrilamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.26.2.4e tripelennamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.14.10e promethazine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-14-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-14-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YW4.8e sedative-hypnotics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-8"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YW4.8.4e nonbarbiturate sedative-hypnotics &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW4-8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW4-8-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6-4-4">YV6.4.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>histamine H2 receptor blockaders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-4-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">ST</TD><TD> H2 blockers </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZT4.12.4e ranitidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-12-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.36.2e famotidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-36-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-36-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.38e cimetidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-38"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-38"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6-6">YV6.6</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>serotonin antagonists&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin agonists.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> 5-HT antagonists </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> 5-hydroxytryptamine antagonists </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>BF4.2e LSD &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BF4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnb.htm#BF4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+BF10 bufotenine &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BF10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnb.htm#BF10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.10.6e phenoxybenzamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-10-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZO2.2.2.12.2 fenclonine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZO2-2-2-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzo.htm#ZO2-2-2-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.6.2e risperidone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.28.6.4e ritanserin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-28-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-28-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.10.12.2e N,N-Dimethyltryptamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-10-12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-10-12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.20.2e ketanserin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-20-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-20-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.4.2.2e clozapine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>EE16.6e antagonistic drug interaction &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EE16-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhned.htm#EE16-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.10.12.4e serotonin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-10-12-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-10-12-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6-6-2">YV6.6.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>serotonin uptake inhibitors&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>SN</TD>
 <TD>A group of drugs that inhibit neuronal re-uptake of serotonin, and consequently prolong its action.  Such drugs have been reported to cause a reduction in alcohol consumption.  Certain
   antidepressants share the property of inhibiting serotonin uptake, while also inhibiting noradrenaline (norepinephrine) uptake.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> 5 HT sub 2 </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> 5 HT sub 3 </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> 5-hydroxytryptamine uptake inhibitors </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> serotonin receptor inhibitors </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> serotonin reuptake inhibitors </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZF8.6.2.2.2e sertraline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZF8-6-2-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnz.htm#ZF8-6-2-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.4.2e fluoxetine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.4.4e citalopram &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-4-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-4-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.12e fluvoxamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.10 ondansetron &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-10"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.18.4e trazodone &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-18-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-18-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.20.2e paroxetine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-20-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-20-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZT4.26.4.2.2e zimelidine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-26-4-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-26-4-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT8.6.2.2e amoxapine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT8-6-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT8-6-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YP4.8.2.2e serotonergic anti-alcohol-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP4.8.12.6 agents for alcohol-concurrent depression &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-12-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YP4.8.12.10 agents for alcohol-related cognitive impairment &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-12-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-12-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6-6-2-2">YV6.6.2.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>viqualine&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6-2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="35%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP4.8.2.2e serotonergic anti-alcohol-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV6-6-2-4">YV6.6.2.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>amterozide&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV6-6-2-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="35%"> </TD><TD WIDTH="5%">BT</TD><TD>+YP4.8.2.10 neuropeptide anti-alcohol-craving agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-8-2-10"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-8-2-10"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV8">YV8</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>parasympatholytics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV8"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> anticholinergic agents </TD></TR>
 <TR><TD> </TD><TD> </TD><TD> anticholinergics </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YD10.2 cholinesterase reactivators &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YD10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YD10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZJ2.10.4.4.2e quinuclidinyl benzilate &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZJ2-10-4-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzj.htm#ZJ2-10-4-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZP18e solanaceous alkaloids &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP18"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP18"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP18.6.4e nicotinamide &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP18-6-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP18-6-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZQ12.2e papaverine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ12-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ12-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>BT</TD><TD>+YW8e CNS stimulants &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YW8"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm#YW8"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV8-2">YV8.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>ganglionic blockaders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV8-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> ganglionic blockers </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>BD2e nicotine &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BD2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnb.htm#BD2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZU6.2e mecamylamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZU6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzu.htm#ZU6-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV10">YV10</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>parasympathomimetics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV10"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="29%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>A substance that produces actions similar to the stimulation of the parasympathetic nervous system.  Also called cholinomimetic.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> cholinomimetic </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YD8.4 cholinesterase inhibitors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YD8-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhny.htm#YD8-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP12e physostigmine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP12"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV10-2">YV10.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>carbachol&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV10-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>Introduced 1995.
  </TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV10-4">YV10.4</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>ganglionic stimulants&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV10-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>BD2e nicotine &nbsp;&nbsp;&nbsp;<A HREF="aodhqb.htm#BD2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnb.htm#BD2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP14e pilocarpine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP14"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP14"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.32.2.2e tremorine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-32-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-32-2-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.32.6.2e oxotremorine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-32-6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-32-6-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV12">YV12</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>sympatholytics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV12"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YK6.2e adrenergic receptors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YK6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyj.htm#YK6-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV12-2">YV12.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alpha-adrenergic receptor blockaders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV12-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">ST</TD><TD> alpha-2 adrenergic antagonists </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD><TT>&nbsp;</TT>ZN2.10.6e phenoxybenzamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-10-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-10-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZP26.4e yohimbine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP26-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP26-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.12e phentolamine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-12"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-12"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT4.14.14e tolazoline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT4-14-14"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT4-14-14"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZT6.20.6e prazosin &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZT6-20-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzt.htm#ZT6-20-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YK6.2e adrenergic receptors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YK6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyj.htm#YK6-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV12-4">YV12.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>beta-adrenergic receptor blockaders&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV12-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD><TT>&nbsp;</TT>ZN2.16.2.6e sotalol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.12.4.2e propranolol &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-12-4-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-12-4-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YK6.2e adrenergic receptors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YK6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyj.htm#YK6-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV12-6">YV12.6</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>adrenergic neurohumor depleters&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV12-6"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">NT</TD><TD>+ZP26e rauwolfia alkaloids &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZP26"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZP26"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YK6.2e adrenergic receptors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YK6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyj.htm#YK6-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV14">YV14</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>sympathomimetics&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV14"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="29%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
<TR><TD WIDTH="29%"> </TD><TD WIDTH="5%" VALIGN=TOP>SN</TD>
<TD>A drug that primarily mimics or produces effects similar to those resulting from stimulation of the sympathetic nervous system.  Sympathomimetic drugs that also excite the central nervous system
   (CNS), such as the amphetamines, are used as recreational drugs.  Also called adrenomimetic drugs.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> adrenomimetic drugs </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+ZN2.10.2e fenfluramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-10-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-10-2"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZN2.18.2.2.4e tyramine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-18-2-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-18-2-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YK6.2e adrenergic receptors &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YK6-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyj.htm#YK6-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV14-2">YV14.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>adrenergic receptor agonists&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV14-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD><TD WIDTH="5%">RT</TD><TD><TT>&nbsp;</TT>EE16.4e synergistic drug interaction &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EE16-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhned.htm#EE16-4"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV14-2-2">YV14.2.2</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>alpha-adrenergic receptor agonists&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV14-2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">ST</TD><TD> alpha adrenergic agonists </TD></TR>
 <TR><TD> </TD><TD>NT</TD><TD>+YH2.2.6e epinephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-2-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-2-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YH2.2.6.6e norepinephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-2-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-2-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.4e phenylephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-4"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-4"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD>+YP4.6e alcohol withdrawal agents &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YP4-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyn.htm#YP4-6"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV14-2-2-2">YV14.2.2.2</A><SMALL></SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>adrenergic alpha-2 adrenergic agonists&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV14-2-2-2"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV14-2-4">YV14.2.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>beta-adrenergic receptor agonists&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV14-2-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
<TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="33%"> </TD><TD WIDTH="5%">NT</TD><TD>+YH2.2.6.6e norepinephrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YH2-2-6-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnye.htm#YH2-2-6-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD><TT>&nbsp;</TT>ZN2.16.2.14e ritodrine &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZN2-16-2-14"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzm.htm#ZN2-16-2-14"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+ZQ12.2.2e papaveroline &nbsp;&nbsp;&nbsp;<A HREF="aodhqz.htm#ZQ12-2-2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnzp.htm#ZQ12-2-2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
<TABLE WIDTH="100%"><TR><TD WIDTH="20%"><A NAME="YV14-4">YV14.4</A><SMALL>e</SMALL></TD><TD><B><TT><SMALL>.&nbsp;&nbsp;.&nbsp;&nbsp;.&nbsp;&nbsp;</TT></SMALL></B>neurotransmitter uptake inhibitors&nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YV14-4"><SMALL>qh</SMALL></A></TD></TR>
</TABLE>
 <TABLE WIDTH="100%" CELLPADDING=0><TR><TD WIDTH="31%"> </TD>
 <TD WIDTH="5%" VALIGN=TOP>HN</TD>
 <TD>ETOH descriptor 2000.
  </TD></TR>
 <TR><TD> </TD><TD>ST</TD><TD> neuronal transmitter uptake inhibitors </TD></TR>
 <TR><TD> </TD><TD>RT</TD><TD><TT>&nbsp;</TT>EE16.6e antagonistic drug interaction &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EE16-6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhned.htm#EE16-6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+EW6e neurotransmission &nbsp;&nbsp;&nbsp;<A HREF="aodhqe.htm#EW6"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhneu.htm#EW6"><SMALL>ah</SMALL></A></TD></TR>
 <TR><TD> </TD><TD> </TD><TD>+YJ2e neurotransmitters &nbsp;&nbsp;&nbsp;<A HREF="aodhqy.htm#YJ2"><SMALL>qh</SMALL></A>&nbsp;&nbsp;&nbsp;<A HREF="aodhnyj.htm#YJ2"><SMALL>ah</SMALL></A></TD></TR>
 </TABLE>
</TABLE><BR><BR>
<CENTER><A HREF="aodob.htm#Y">b-out</A>&nbsp;&nbsp;To Broad Outline&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="aodod.htm#YN">d-out</A>&nbsp;&nbsp;To Detailed Outline&nbsp;&nbsp;&nbsp;&nbsp;
<A HREF="aodhqy.htm">qh</A>&nbsp;&nbsp;To Quick Hierarchy</CENTER>
<CENTER><A HREF="aodhnyj.htm">Previous</A>&nbsp;Annotated Hierarchy section&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="aodhnyw.htm">Next</A>&nbsp;Annotated Hierarchy section&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="aodwsrch.htm">Search</A></CENTER><P>classification thesaurus glossary dictionary definition subject heading list ontology vocabulary knowledge structure knowledge organization terminology concept </P>
</BODY>
</HTML>
